

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Sep 2026

Investigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)

Protocol summary

Study aim

To determine the effect of Deferiprone on the severity of symptoms and mortality of patients with covid 19

Design

This trial (Phase 3) is performed on 80 patients using a parallel design (40 patients in each group): Intervention group: In addition to the main drugs recommended by the National Committee for Coronavirus, the group will receive the oral drug Deferiprone as an adjunct treatment. Control group: The group that will receive only the main drugs recommended by the National Committee for Coronavirus. The randomization method is based on the formation of Permuted Blocked randomization (each block will consists 4 patients).

Settings and conduct

The study is being conducted at Tohid Hospital in Sanandaj (the provincial treatment center for patients with Qovid 19). Patients, physicians, and nurses who evaluate the outcomes will be blind to the groups studied.

Participants/Inclusion and exclusion criteria

Patients with covid 19 with 18 to 80 years of age will enter to the study. Patients who had a history of liver or kidney disease, as well as patients with anemia and also patients who have gastroenteritis will be excluded from this trial.

Intervention groups

Deferiprone

Main outcome variables

Improving the symptoms of Covid 19; duration of hospital stay; SPO2 to FiO2 ratio; duration required for RT-PCR test to be negative; mortality; adverse side effects

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20180114038350N3**

Registration date: **2020-05-01, 1399/02/12**

Registration timing: **prospective**

Last update: **2020-05-01, 1399/02/12**

Update count: **0**

Registration date

2020-05-01, 1399/02/12

Registrant information

Name

Khaled Rahmani

Name of organization / entity

Kurdistan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 87 3312 5880

Email address

khaledrahmani111@muk.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-05-04, 1399/02/15

Expected recruitment end date

2020-06-04, 1399/03/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)

Public title

Effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Covid 19 patients without needing ventilator Age between 18 to 80

Exclusion criteria:

Patients with anemia Patients with gastroenteritis Patients who had history of liver diseases Patients who had history of renal diseases

Age

From **18 years** old to **80 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor

Sample size

Target sample size: **80**

Randomization (investigator's opinion)

Randomized

Randomization description

We will use permuted block randomization (each block consists 4 patients) method to allocate the patients into two study groups (control and intervention)

Blinding (investigator's opinion)

Double blinded

Blinding description

Study participants, physicians and nurses who evaluate the outcomes will be blind to the intervention and studied groups.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Kurdistan University of Medical Sciences

Street address

Kurdistan University of Medical Sciences , Pasdaran Blvd.

City

Sanandaj

Province

Kurdistan

Postal code

6617713446

Approval date

2020-04-20, 1399/02/01

Ethics committee reference number

IR.MUK.REC.1399.012

Health conditions studied**1****Description of health condition studied**

Patients with Covid 19

ICD-10 code

U07.01

ICD-10 code description

Covid 19

Primary outcomes**1****Description**

Improvement in disease symptoms (Fever and breathing)

Timepoint

This primary outcome is measured for patients before and during 5 days after treatment initiation

Method of measurement

Fever is calculated using mercury thermometers and respiration is calculated using the number of breaths per minute.

Secondary outcomes**1****Description**

Duration of hospital stay

Timepoint

Based on the number of days a person is hospitalized

Method of measurement

Medical records

2**Description**

Improvement in SPO2 to FiO2 ratio

Timepoint

Percent of SPO2

Method of measurement

Based on Oximeter pulse

3**Description**

Death

Timepoint

Number of death in each group

Method of measurement

Medical Records

Intervention groups

1

Description

Intervention group: Oral Deferiprone is added to drugs used to treat Covid 19 (approved by the National Committee).

Category

Treatment - Drugs

2

Description

Control group: Patients receive only the drugs used to treat Covid 19 (approved by the National Committee).

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Tohid Hospital, a teaching hospital in Sanandaj

Full name of responsible person

Karim Naseri

Street address

Pasdarán Blvd

City

Sanandaj

Province

Kurdistan

Postal code

6617713446

Phone

+98 87 3366 4645

Email

bihoshi@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

Afshin Maleki

Street address

Kurdistan University of Medical Sciences, Sanandaj,
Pasdarán Blvd,

City

Sanandaj

Province

Kurdistan

Postal code

6616797161

Phone

+98 87 3366 4653

Email

maleki43@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Sanandaj University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

Khaled Rahmani

Position

Assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Epidemiology

Street address

Kurdistan University of Medical Sciences, Sanandaj,
Pasdarán Blvd

City

Sanandaj

Province

Kurdistan

Postal code

666147 - 13446

Phone

+98 87 3366 4673

Email

khaledrahmani111@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

Karim Naseri

Position

Associate Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Kurdistan University of Medical Sciences, Sanandaj,
Pasdaran Blvd

City

Sanandaj

Province

Kurdistan

Postal code

666147 - 13446

Phone

+98 87 3366 4673

Email

bihoshi@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

Khaled Rahmani

Position

Assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Epidemiology

Street address

Kurdistan University of Medical Sciences, Sanandaj,
Pasdaran Blvd

City

Sanandaj

Province

Kurdistan

Postal code

666147 - 13446

Phone

+98 87 3366 4673

Email

khaledrahmani111@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Not applicable

Title and more details about the data/document

In case of publisher journal request, data would be sent to the journal.

When the data will become available and for how long

During the publication of paper and 6 months after publish

To whom data/document is available

Editor of the journal that publish the paper and academic researchers with permission of correspondence author

Under which criteria data/document could be used

Data can only used to meta analysis with permission of correspondence author

From where data/document is obtainable

The correspondence author of the study

What processes are involved for a request to access data/document

By sending the mail to the correspondence author

Comments